Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUNI-SEP: Ulinastatin for Sepsis
NCT05895240Phase 4Unknown
- Sponsor
- Jinnah Postgraduate Medical Centre
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ulinastatin in sepsis (2 arms), sponsored by Jinnah Postgraduate Medical Centre. Primary endpoints: Prevention of Multiple Organ Dysfunction Syndrome at Day 5, In-hospital Mortality at 48 hours and 3 more. Status: unknown.
02
Drugs
ulinastatin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05895240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895240.